Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -187.24% is 97% above its 5-year average of -5954.65%, near the high end of its 5-year range (-5611700.00%–192905.26%).
99.80% above its 12-month average of -93758.54%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2037.16%.
OPERATING MARGIN
-187.24%
OPERATING MARGIN AVG TTM
-93758.54%
OPERATING MARGIN AVG 3Y
-150702.70%
OPERATING MARGIN AVG 5Y
-5954.65%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.80%
CURRENT VS 3Y AVG
+99.88%
CURRENT VS 5Y AVG
+96.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
4D Molecular Therapeutics, Inc.
Market Cap
$675.41M
Operating Margin
-187.24%
TTM Avg
-93758.54%
3Y Avg
-150702.70%
5Y Avg
-5954.65%
Market Cap
$698.60M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$643.37M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$707.86M
Operating Margin
317.06%
TTM Avg
-14996.68%
3Y Avg
-12629.31%
5Y Avg
-15360.40%
Market Cap
$642.31M
Operating Margin
-12.47%
TTM Avg
-13.07%
3Y Avg
-26.14%
5Y Avg
-20.95%
Market Cap
$709.33M
Operating Margin
19.61%
TTM Avg
25.44%
3Y Avg
21.88%
5Y Avg
18.67%
Market Cap
$637.59M
Operating Margin
-28.23%
TTM Avg
-27.16%
3Y Avg
-23.27%
5Y Avg
7.30%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $675.41M | -187.24% | -93758.54% | -150702.70% | -5954.65% |
| Annexon, Inc. (ANNX)vs › | $688.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| Helus Pharma Inc. (HELP)vs › | $707.86M | 317.06% | -14996.68% | -12629.31% | -15360.40% |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | -12.47% | -13.07% | -26.14% | -20.95% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 19.61% | 25.44% | 21.88% | 18.67% |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | -28.23% | -27.16% | -23.27% | 7.30% |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | 0.00% | 0.00% | 0.00% | 0.00% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
91.0%
Operating Margin
-187.2%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -2037.16% |
| 2026-03-31 | -2416.15% |
| 2025-12-31 | 17.29% |
| 2025-09-30 | -67983.33% |
| 2025-06-30 | -396373.33% |
| 2025-03-31 | -383007.14% |
| 2024-12-31 | -5611700.00% |
| 2024-09-30 | -1704400.00% |
| 2024-06-30 | -849120.00% |
| 2024-03-31 | -136200.00% |
| 2023-12-31 | 192905.26% |
| 2023-09-30 | -69.16% |
| 2023-06-30 | -13446.03% |
| 2023-03-31 | -10102.68% |
| 2022-12-31 | -2303.13% |
| 2022-09-30 | -5299.00% |
| 2022-06-30 | -17546.91% |
| 2022-03-31 | -2165.05% |
| 2021-12-31 | -26917.39% |
| 2021-09-30 | -1658.93% |
| 2021-06-30 | -52.10% |
| 2021-03-31 | -815.60% |
| 2020-12-31 | 2090.28% |
| 2020-09-30 | -105.32% |
| 2020-06-30 | -416.98% |
| 2020-03-31 | -375.59% |
| 2019-12-31 | -802.36% |
| 2019-09-30 | -3152.41% |
| 2019-06-30 | -395.22% |
| 2019-03-31 | -395.22% |
| 2018-12-31 | -55.87% |
| 2018-09-30 | -55.87% |
| 2018-06-30 | -105.29% |
| 2018-03-31 | -105.29% |
